Catalyst Event
Novo Nordisk A/S (NVO) · Other
From KEDI Global Obesity Care Industry Top 2+ Index (OBCI)
3/23/2026, 12:00:00 AM
Initiated a Phase 1 clinical trial for LX9851, an oral drug candidate for obesity licensed from Lexicon Pharmaceuticals. Analysts estimate a minor positive market reaction, estimated.
Korean Translation
렉시콘 파마슈티컬스로부터 라이선스한 경구용 비만 치료제 후보물질 LX9851에 대한 1상 임상시험을 개시함. 애널리스트들은 소폭의 긍정적인 시장 반응을 보일 것으로 예상됨.
Related Recent Events
Amgen Inc (AMGN) · Other
A quarterly dividend of $2.52 per share for Q2 2026 is scheduled, with an ex-dividend date of May 15, 2026; a price impact of ≥1% is estimated due to the routine nature of the distribution, scheduled.
5/15/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Merck is scheduled to release its Q1 2026 financial results before the market opens. Earnings releases typically cause significant price volatility, justifying a Medium importance, scheduled.
4/30/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
The U.S. FDA is expected to make an approval decision on orforglipron, Eli Lilly's oral GLP-1 drug for weight loss, by April 10, 2026, expected; medium importance reflects the potential market expansion for obesity treatments.
4/10/2026, 12:00:00 AM
Abbott Laboratories (ABT) · Other
S&P Global Ratings downgraded Abbott's credit rating to 'A+' from 'AA-' on 2026-03-24 following the completion of the Exact Sciences acquisition, citing increased leverage.
3/24/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
Eli Lilly announced positive topline results from the TRANSCEND-T2D-1 Phase 3 trial on March 19, 2026, showing its next-generation 'Triple-G' agonist, retatrutide, led to significant reductions in A1C and body weight.
3/19/2026, 12:00:00 AM
Novo Nordisk A/S (NVO) · Other
The U.S. FDA approved Wegovy® HD (semaglutide 7.2 mg), a higher dose for weight management, which showed a mean weight loss of 20.7% in trials. Analysts estimate this approval will drive significant revenue growth, and the U.S. launch is expected in April 2026.
3/19/2026, 12:00:00 AM